Replies to post #6047 on GTC Biotherapeutics (fka GTCB)

[dodah_2]

With the PPS where it is, now would be a good time to exercise some of those options.

[DewDiligence]

Current Insider Shareholdings and Options

[Updated for insider buys on 12/14/07. Except for the
options issued this year (which can be tracked from
recent Form-4 filings), exercise prices of the various
options are spelled out in the DEF14a SEC filing for
the 2007 annual meeting. Essentially all options are
currently underwater.]

 
  
 Executive Officers  
 Geoffrey Cox, CEO          277K shares   722K options 
 John Green, CFO            116K shares   307K options 
 Harry Meade, SVP Research  123K shares   268K options 
 Dan Woloshen, Gen. Counsel  81K shares   190K options 
 Greg Liposky, SVP Oprtns    51K shares   246K options 
 Dick Scotland, SVP Regltry  69K shares   129K options 
 -- 
 Six executive officers     717K shares 1,852K options

 
 Non-executive directors  
 Robert Baldridge             5K shares    75K options 
 Kenneth Bauer                 0 shares    38K options 
 Christian Béchon            13K shares    15k options 
 Francis Bullock              9K shares    74K options 
 James Geraghty              75K shares   163K options 
 Michael Landine               0 shares    38K options 
 Pamela McNamara              8K shares    53K options 
 Marvin Miller                7K shares    53K options 
 Alan Tuck                   13K shares    51K options 
 Mary Ann Gray                1K shares    15K options 
 -- 
 Ten non-executive directrs 131K shares   575K options

 
 All officers/directors     848K shares 2,427K options